as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 28 Sep 2026
₹926.1
Change
-21.9 (-2.31%)
Open
₹949.0
Prev. Close
₹948.0
Day High
₹959.0
Day Low
₹911.1
Volume Analysis
Traded
1,732
Delivered
1,346
Delivery %
77.71%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (1)
- •Promoter holding is falling
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,000.94 | ₹979.97 | ₹953.04 | ₹932.07 | ₹905.14 | ₹884.17 | ₹857.24 |
| Fibonacci | ₹979.97 | ₹961.67 | ₹950.37 | ₹932.07 | ₹913.77 | ₹902.47 | ₹884.17 |
| Camarilla | ₹939.27 | ₹934.88 | ₹930.49 | ₹932.07 | ₹921.71 | ₹917.32 | ₹912.93 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-3.25%
1 Month
-11.63%
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Company Overview
Sector
Healthcare
Source: Screener.in (Consolidated figures) — data as of 29 Sep 2026. Not investment advice.
TopFund Analysis
Jenburkt Pharmaceutical L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 55/100. The strongest factor is Risk & Volatility (92/100), while Institutional Ownership (20/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling. FII holding has been falling.
TopFund Score — Fundamentals Quality
55/100 — AverageData confidence: 59/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 28 Sep 2026 · How we calculate this →
Corporate Governance
Institutional Ownership
Risk & Volatility
Liquidity
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Jenburkt shares admitted for trading on NSE under Permitted to Trade from 17 August 2026.
Vinay Bhatt, SVP-International Business, resigned effective 18 September 2026.
41st AGM resolutions passed; 207% dividend declared, Dilip H. Bhuta reappointed WTD and CFO.
Shareholders approved Dilip H. Bhuta’s reappointment as Whole Time Director and CFO from 1 April 2027 to 31 March 2032.
Source: BSE regulatory filings, via Screener.in.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 51.21% | 52.63% | 52.78% | 53.29% | 53.28% | 53.2% | 53.2% | 53.21% | 53.22% | 53.24% | 53.24% | 53.27% |
| Promoters | 47.42% | 47.39% | 47.23% | 46.71% | 46.71% | 46.69% | 46.68% | 46.67% | 46.66% | 46.65% | 46.64% | 46.62% |
| FII | 1.38% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Jenburkt Pharmaceutical L (this stock) | — | — | — | — |
| Sun Pharmaceutical Ind L | 444,405 | 35.2 | 5.32 | 16.0% |
| Divi S Laboratories Ltd | 253,694 | 85.2 | 15.14 | 16.5% |
| Torrent Pharmaceuticals L | 189,746 | 85.0 | 20.11 | 27.4% |
| Apollo Hospitals Enter. L | 128,055 | 60.9 | 13.51 | 21.2% |
| Zydus Lifesciences Ltd | 120,089 | 24.7 | 4.48 | 21.2% |
| Cipla Ltd | 111,985 | 31.3 | 3.25 | 11.6% |
Which Mutual Funds Hold Jenburkt Pharmaceutical L?
Frequently Asked Questions about Jenburkt Pharmaceutical L
Jenburkt Pharmaceutical L (JENBURPH) closed at ₹926.1 on NSE on 28 September 2026, down 21.9 (2.31%) from the previous close.
Jenburkt Pharmaceutical L trades on the NSE (National Stock Exchange of India) under the symbol JENBURPH.
Jenburkt Pharmaceutical L has a TopFund Quality Score of 55/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Jenburkt Pharmaceutical L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.